A case report details comprehensive dental management under general anesthesia for a pediatric patient with type 3 von Willebrand disease. This study highlights the challenges and considerations in treating dental issues in patients with bleeding disorders.

A recent study highlights persistent gingival bleeding after dental scaling as a potential diagnostic indicator for von Willebrand disease. This finding could enhance early detection and management of the condition.

FDA classifies the von Willebrand factor assay into class II, establishing special controls to ensure safety and effectiveness. This classification aims to enhance regulatory oversight for devices related to von Willebrand disease.

If you’re looking for a sign that biotech’s IPO renaissance remains on track then the pair of upsized Nasdaq listings on Friday morning is a good place to start. | "We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce. The IPO funds are expected to help finance a phase 3 study in Glanzmann thrombasthenia, as well as an ongoing phase 2 trial in another bleeding disorder called Factor VII deficiency. Meanwhile, Hemab wants to push its monovalent antibody, HMB-002, through a phase 1/2 study for von Willebrand disease, another genetic disorder that impacts blood clotting. Seaport Therapeutics Hemab Therapeutics IPO biotech IPO Biotech Zohar co-founded Karuna Therapeutics, the neuroscience biotech bought by Bristol Myers Squibb for $14 billion to acquire the schizophrenia drug that would hit the market as Cobenfy. When asked by Fierce why Seaport hadn’t also opted for a Big Pharma acquisition, Zohar suggested that companies try and keep both options open. Both depression-focused Seaport Therapeutics and clotting company Hemab Therapeutics had been priming investors earlier this week to expect IPOs of around the $180 million range. But the companies significantly overshot their targets. Boston-based Seaport sold nearly 14.2 million shares for its offering—flying past the 11.8 million shares that the company had been expecting as recently as Monday. With the shares priced at $18 apiece, it means the biotech will rake in $254.9 million in gross proceeds from the IPO. Seaport’s stock began trading on the Nasdaq this morning under the ticker “SPTX.” It was joined by another biotech entrant in the form of Hemab. Like Seaport, Hemab had been banking on an IPO of around $180 million, but the end result has come out above $300 million, according to an April 30 release.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines. Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines. ... The value of IPOs so far this year suggests the sector is winning the battle against macroeconomic policy shifts in the US. Credit: Billion Photos/Shutterstock.com. Seaport Therapeutics and Hemab Therapeutics have both outlined pricings for their respective initial public offerings (IPOs), adding to an already busy month for biotechs making the public jump. Sutacimig, also known as HMB-001, is set to command most of the IPO funds. Around $120m will be put towards the asset’s clinical development in the two bleeding disorders. Around $60m will be used to advance clinical development of HMB-002, the biotech’s monovalent antibody in Phase I/II development for the subcutaneous prophylactic treatment of Von Willebrand Disease. GlyphAllo, also known as SPT-300, has been designed using Seaport’s Glyph platform, which the biotech says overcomes bioavailability and first-pass metabolism limitations. These hurdles have historically plagued treatments targeted against neuropsychiatric disorders. Seaport’s platform employs the lymphatic system’s natural lipid absorption and transport process to bypass the liver, which should also help reduce hepatotoxicity. Around $121m of the IPO raise will help fund GlyphAllo through a Phase IIb trial (NCT07065240) and into Phase III development. Seaport, a biotech developing treatments in the neuropsychiatric space, is offering 11.8 million shares priced between $16 and $18 each on the Nasdaq. If the IPO settles in the midpoint of this range, the biotech estimates net proceeds of $183.5m, which could rise by a further $27.9m based on the underwriters’ option.